Indivior PLC (INDV) – What Are Researchers Saying About This Stock?

Shares of Indivior PLC (NASDAQ:INDV) have received a consensus rating of “Buy” from the six brokerages that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, four have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $46.40.

Several equities analysts have recently issued reports on the company. Weiss Ratings cut Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, September 24th. Zacks Research upgraded Indivior from a “hold” rating to a “strong-buy” rating in a report on Friday, October 2nd. Barclays raised their price target on Indivior from $43.00 to $45.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 28th. Wall Street Zen cut shares of Indivior from a “strong-buy” rating to a “buy” rating in a report on Saturday, October 31st. Finally, Craig Hallum reissued a “buy” rating and issued a $53.00 price target on shares of Indivior in a research note on Tuesday, August 4th.

Insider Transactions at Indivior

In other news, CAO Woodrow D. Anderson bought 1,500 shares of the company’s stock in a transaction dated Thursday, August 27th. The shares were purchased at an average price of $35.69 per share, for a total transaction of $53,535.00. Following the completion of the purchase, the chief accounting officer owned 27,638 shares in the company, valued at approximately $986,400.22. This represents a 5.74% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.74% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Indivior

A number of large investors have recently added to or reduced their stakes in the stock. Intech Investment Management LLC lifted its position in shares of Indivior by 0.4% during the 3rd quarter. Intech Investment Management LLC now owns 108,262 shares of the company’s stock valued at $3,881,000 after acquiring an additional 444 shares during the period. Illinois Municipal Retirement Fund boosted its stake in shares of Indivior by 1.0% during the 3rd quarter. Illinois Municipal Retirement Fund now owns 62,933 shares of the company’s stock worth $2,256,000 after acquiring an additional 611 shares in the last quarter. Rockefeller Capital Management L.P. grew its holdings in shares of Indivior by 512.4% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,286 shares of the company’s stock worth $46,000 after acquiring an additional 1,076 shares during the period. Virtus Advisers LLC grew its holdings in shares of Indivior by 24.9% in the 3rd quarter. Virtus Advisers LLC now owns 7,871 shares of the company’s stock worth $282,000 after acquiring an additional 1,570 shares during the period. Finally, TD Waterhouse Canada Inc. purchased a new position in Indivior in the 2nd quarter valued at approximately $63,000. Institutional investors own 60.33% of the company’s stock.

Indivior Trading Up 0.2%

Shares of NASDAQ:INDV opened at $28.21 on Monday. The stock has a market capitalization of $3.33 billion, a P/E ratio of 7.88 and a beta of 0.84. The stock’s 50-day moving average price is $34.24 and its 200-day moving average price is $35.48. Indivior has a 12-month low of $27.68 and a 12-month high of $42.81.

Indivior (NASDAQ:INDV) last issued its earnings results on Thursday, October 29th. The company reported $1.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.06 by $0.26. Indivior had a net margin of 32.75% and a negative return on equity of 418.04%. The firm had revenue of $356.00 million for the quarter, compared to analysts’ expectations of $329.35 million. As a group, research analysts predict that Indivior will post 3.66 EPS for the current year.

Indivior Announces Dividend

The business also recently disclosed a special dividend, which was paid on Friday, November 6th. Shareholders of record on Friday, October 30th were paid a dividend of $8.13 per share. The ex-dividend date was Tuesday, November 3rd.

About Indivior

Indivior is a specialty pharmaceutical company focused on developing and providing treatments for substance use disorders and serious mental illness. Its products include medicines for opioid use disorder, such as Sublocade, a long-acting injectable form of buprenorphine, and Suboxone, a buprenorphine-and-naloxone treatment. The company also markets Opvee, a nasal spray used to reverse opioid overdose, and Perseris, a long-acting injectable treatment for schizophrenia. Indivior develops additional therapies through its research and development programs.